Investasi
Fitur
BiayaKeamanan
Akademi
Lainnya
Pluang+

Bandingkan Harga & Kinerja Reliance Sekuritas Indonesia Tbk. (RELI) vs Organon Pharma Indonesia Tbk. (SCPI)

Reliance Sekuritas Indonesia Tbk.Trading
Organon Pharma Indonesia Tbk.Trading

Kinerja harga (24 Jam Terakhir)

Statistik utama

Perbedaan Reliance Sekuritas Indonesia Tbk. dan Organon Pharma Indonesia Tbk.: Reliance Sekuritas Indonesia Tbk. diperdagangkan di Rp560 (kapitalisasi pasar 999 M, volume 24 jam 33,8 rb), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Reliance Sekuritas Indonesia Tbk. jauh lebih besar — sekitar 9,6× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.

RELISCPI
Kapitalisasi Pasar
999 M104,4 M
Volume
33,8 rb
Lot
338
Perputaran
18,78 jt
Harga Rata-rata
555,58
Nilai Transaksi
18,78 jt
Harga Ekuilibrium Indikatif
560
Volume Ekuilibrium Indikatif
1

Perbandingan imbal hasil

Imbal hasil berjalan pada periode standar

Berita terkini

Berita terbaru kedua aset

RELI
Lihat detail
SCPI
Lihat detail

Tentang Reliance Sekuritas Indonesia Tbk.

PT. Reliance Securities (the company) was established under its original name of Istethmar Finas Securities on 22 Feb 1993 then changed to PT Ludlow Securities on 13 Sep 1999. According with Notaries deed on 28 March 2003 company's name changed to PT Reliance Securities. And the company's name changed to PT Reliance Securities Tbk on 19 May 2005 with amended the articles of association no 19 dated 14 April 2005.

Selengkapnya di halaman RELI

Tentang Organon Pharma Indonesia Tbk.

PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.

Selengkapnya di halaman SCPI